OncoSec Medical Inc (ONCSQ) Stock Price, Trades & News

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	12-1 Month Momentum %	900

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-Revenue	0.32

GF Value™

ONCSQ

Warning Signs

Warning! GuruFocus detected issues with ONCSQ. Try a 7-Day Free Trial to check it out.

OncoSec Medical Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

OncoSec Medical Inc Stock Events

Financials Calendars

Event	Date	Price ($)
First quarter earnings results for 2027	2026-12-15	In 171 days
Annual report for 2026	2026-10-19	In 114 days
Third quarter earnings results for 2026	2026-07-06	In 9 days
General meeting for 2025	2026-06-29	In 2 days
Second quarter earnings results for 2026	2026-06-29	In 2 days
Third quarter earnings results for 2026	2026-06-15	0.00 (+0.00%)
General meeting for 2025	2026-05-04	0.00 (+0.00%)
Second quarter earnings results for 2026	2026-05-04	0.00 (+0.00%)
First quarter earnings results for 2026	2026-04-13	0.00 (+0.00%)
0.0454545:1 Stock Split	2022-11-09	5.95 (-24.88%)

Show

Entries

Guru Commentaries on OTCPK:ONCSQ

No articles.

Press Release

	Subject	Date
	OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	2023-05-18
	OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	2023-05-16
	OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program	2023-05-16
	OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program	2023-04-27
	OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	2023-04-11
	Thinking about buying stock in OncoSec Medical, Diversified Healthcare, Cardio Diagnostics, Plug Power, or Macy's?	2023-03-02
	Thinking about buying stock in Reata Pharmaceuticals, OncoSec Medical, Lucira Health, B&G Foods, or Payoneer Global?	2023-03-01
	OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022	2022-12-05
	OncoSec Announces Pricing of $3.5 Million Public Offering	2022-11-30
	OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma	2022-11-15

10/Page

Articles on OncoSec Medical Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.